


# Acid-labile Subunit ELISA E35



IGF-I, IGFBP-3 and the acid labile subunit (ALS) build up the so called ternary complex, the major storage of IGF-I in circulation. ALS expression is located in the liver and controlled by human growth hormone. Thus, determination of serum ALS levels could be helpful in the differential diagnosis of patients with idiopathic IGF-I deficiency.

This test system is based on polyclonal antibodies, highly specific for the acid labile subunit. Peptides of previously published sequences have been used for immunization of rabbits<sup>1</sup>:

N-terminal:  
ADPGTPGEAEGPACPAACVCSYD DDADELSVFCS  
C-terminal:  
YNNITCASPPVVGLDLRDLSEAHFAPC


## Specimen

Human serum and plasma samples can be used in this assay. No influence of Heparin (30 IE/mL), EDTA (6.8 mM) and NaCitrate (0.015 M) on the measurement of ALS has been detected by recovery experiments.

| Interference              | % of control |
|---------------------------|--------------|
| Triglycerides [100 mg/mL] | 100          |
| Hemoglobin [1 mg/mL]      | 105          |
| Bilirubin [200 µg/mL]     | 94           |

## Indication

ALS is a marker protein for growth hormone action. It could therefore be used for therapy surveillance and initial diagnostics of growth hormone deficiency or acromegaly.



**Linearity**, measured signal intensity [OD<sub>450</sub>] of differentially diluted samples. The recommended dilution is 1:150 (0.007).

## Sample Stability

Storage at 25°C up to 3 days  
Storage at -20°C up to 2 years  
Not more than 5 freeze/thaw cycles!

## Assay Features

- ✓ Calibration against recombinant ALS
- ✓ native human ALS standard: 0 – 200 ng/mL
- ✓ Assay Range 0.53 – 30 000 ng/mL
- ✓ analytical sensitivity of 0.53 ng/mL
- ✓ high precision:
  - inter-assay variance ≤ 8.0%
  - intra-assay variance ≤ 6.8%
- ✓ excellent linearity
- ✓ 2 control sera for GLP conformity
- ✓ Fast: Incubation Time of 3 hours

## Literature

- (1) Stadler S, Wu Z, Dressendörfer RA, Morrison KM, Khare A, Lee PDK, **Strasburger, CJ**: J Immunological Methods 252 (2001) 73-82
- (2) Morrison KM, **Bidlingmaier M**, Stadler S, Wu Z, Skriver L, **Strasburger CJ**: European Journal of Endocrinology (2007) 156

## Mediagnost Acid-labile Subunit ELISA, E35

|   |   |                     |
|---|---|---------------------|
| Reconstitution/ Dilution of Reagents  |   |                     |
| <b>Standards A-F</b>  | Reconstitution in <b>Sample Buffer PP</b> (red)   | <b>1000 µL each</b> |
| <b>Control Serum KS1/KS2</b>  | Reconstitution in <b>Sample Buffer PP</b> (red)   | <b>250 µL each</b>  |
| <b>Antibody Conjugate AK</b>  | dilute before use: <b>1:50</b> in <b>Dilution Buffer VP</b>   | <b>1:50</b>         |
| <b>Washing Buffer WP</b>  | Dilute in <b>A. dest.</b> (e.g. add the complete contents of the flask 50 mL into a graduated flask and fill with A.dest. to 1000 mL) | <b>1:20</b>         |
| <b>Sample and Control Sera KS1 &amp; KS2 Dilution: 1:150 in Sample Buffer PP</b> (red colored; e.g. 10 µL in 1490 µL PP). <b>mix directly and use within max. 60 min.</b><br>Use <b>50 µL per determination</b> (pipetting control= red coloration) |   |                     |
| Before assay procedure bring all <b>reagents to room temperature</b>  |   |                     |

| Pipette                               | Reagents                                    | Well Positions  |
|---------------------------------------|---|---|
| 50 µL                                 | <b>1:50 diluted Antibody Conjugate (AK)</b> | Pipette in <b>all</b> required number of wells                    |
| 50 µL                                 | Standard <b>A (0 ng/mL)</b>                 | A1 and A2   |
| 50 µL                                 | Standard <b>B (7.5 ng/mL)</b>               | B1 and B2   |
| 50 µL                                 | Standard <b>C (31.25 ng/mL)</b>             | C1 and C2   |
| 50 µL                                 | Standard <b>D (62.5 ng/mL)</b>              | D1 and D2   |
| 50 µL                                 | Standard <b>E (125 ng/mL)</b>               | E1 and E2   |
| 50 µL                                 | Standard <b>F (200 ng/mL)</b>               | F1 and F2   |
| 50 µL                                 | Diluted Control Serum <b>KS1</b>            | G1 and G2   |
| 50 µL                                 | Diluted Control Serum <b>KS2</b>            | H1 and H2   |
| 50 µL                                 | Diluted Sample                              | Pipette sample in the rest of the wells according to requirements |
| Cover the wells with the sealing tape |   |   |

Incubation: 2 h at RT, 350 rpm

|           |  |           |
|-----------|--|-----------|
| 5x 300 µL | Aspirate the contents of the wells and wash <b>5x</b> with <b>300 µL</b> each <b>WP/well</b> | each well |
| 100 µL    | <b>Enzyme Conjugate EK</b>   | each well |

Incubation: 0.5 h at RT, 350 rpm

|           |  |           |
|-----------|--|-----------|
| 5x 300 µL | Aspirate the contents of the wells and wash <b>5x</b> with <b>300 µL</b> each <b>WP/well</b> | each well |
| 100 µL    | <b>Substrate Solution S</b>  | each well |

Incubation: 30 min in the dark at RT

|   |                         |           |
|---|-------------------------|-----------|
| 100 µL  | Stop Solution <b>SL</b> | each well |
| Measure the absorbance within 30 min at <b>450 nm</b> (≥590 nm Reference) |                         |           |